{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:01:08Z","timestamp":1780473668279,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Santen pharmaceutical (china) co., ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prostaglandin analogs (PGAs) are the first-line treatment for primary open-angle glaucoma (POAG) and ocular hypertension (OH). This study aimed to confirm the effectiveness and safety of Tapros\u00ae (0.0015% tafluprost eye drops) in Chinese patients with POAG and OH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This phase IV, multicenter, non-comparative, prospective study enrolled patients with POAG and OH in China between 12\/27\/2017 and 04\/15\/2020. Patients who were treatment-na\u00efve or untreated within one month (group A) or with unreached intraocular pressure (IOP) target after previous monotherapy of other PGAs (group B) or non-PGA IOP-lowering drugs (group C) were treated with 0.0015% tafluprost for three months. The IOP reduction, response rate, and safety were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 165, 89, and 31 patients in groups A, B, and C, with baseline IOPs of 22.4\u2009\u00b1\u20094.7, 21.0\u2009\u00b1\u20093.5, and 22.5\u2009\u00b1\u20093.2\u00a0mmHg, respectively. The least-square means and percentages of IOP reduction at 3\u00a0months for groups A, B, and C were 4.7 (19.8%), 1.6 (6.1%), and 4.6\u00a0mmHg (20.3%), respectively. A significant reduction in IOP was observed at each visit compared with baseline (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). At the final visit, 57.0% of the participants in group A achieved an IOP reduction of\u2009\u2265\u200920%, while 40.4% and 77.4% in groups B and C achieved an IOP reduction of\u2009\u2265\u200910%. Fifty-eight treatment-related adverse events occurred in 46 participants (15.7%), of which the most common one was conjunctival hyperemia (34\/293, 11.6%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Tafluprost showed a sustained and significant effect with tolerable adverse events in Chinese patients with POAG and OH who were treatment-na\u00efve or untreated within one month or received prior treatments with unsatisfying outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02553-1","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T14:02:55Z","timestamp":1659708175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China"],"prefix":"10.1186","volume":"22","author":[{"given":"Xinghuai","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weining","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huacong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"2553_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u20137.","journal-title":"Br J Ophthalmol"},{"key":"2553_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2020.21899","volume":"325","author":"JD Stein","year":"2021","unstructured":"Stein JD, Khawaja AP, Weizer JS. Glaucoma in Adults-Screening, Diagnosis, and Management: A Review. JAMA. 2021;325:164\u201374.","journal-title":"JAMA"},{"key":"2553_CR3","doi-asserted-by":"crossref","unstructured":"Tu W-J, Zeng X, Liu Q. Aging tsunami coming: the main finding from China\u2019s seventh national population census. Aging Clin Exp Res. 2022;34:1159\u201363.","DOI":"10.1007\/s40520-021-02017-4"},{"key":"2553_CR4","unstructured":"OECD. Elderly Population (Demography) 2020 [Available from: https:\/\/www.oecd-ilibrary.org\/social-issues-migration-health\/elderly-population\/indicator\/english_8d805ea1-en."},{"key":"2553_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1136\/bjophthalmol-2018-313308","volume":"104","author":"CY Cheng","year":"2020","unstructured":"Cheng CY, Wang N, Wong TY, Congdon N, He M, Wang YX, et al. Prevalence and causes of vision loss in East Asia in 2015: magnitude, temporal trends and projections. Br J Ophthalmol. 2020;104:616\u201322.","journal-title":"Br J Ophthalmol"},{"key":"2553_CR6","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.07.020705","volume":"7","author":"P Song","year":"2017","unstructured":"Song P, Wang J, Bucan K, Theodoratou E, Rudan I, Chan KY. National and subnational prevalence and burden of glaucoma in China: A systematic analysis. J Glob Health. 2017;7: 020705.","journal-title":"J Glob Health"},{"key":"2553_CR7","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901\u201311.","journal-title":"JAMA"},{"key":"2553_CR8","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1001\/jama.288.20.2607","volume":"288","author":"PR Lichter","year":"2002","unstructured":"Lichter PR. Impact of intraocular pressure reduction on glaucoma progression. JAMA. 2002;288:2607\u20138.","journal-title":"JAMA"},{"key":"2553_CR9","first-page":"447","volume":"3","author":"O Eyawo","year":"2009","unstructured":"Eyawo O, Nachega J, Lefebvre P, Meyer D, Rachlis B, Lee CW, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clinical ophthalmology (Auckland, NZ). 2009;3:447\u201356.","journal-title":"Clinical ophthalmology (Auckland, NZ)"},{"key":"2553_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002512-200522010-00001","volume":"22","author":"RE Marquis","year":"2005","unstructured":"Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005;22:1\u201321.","journal-title":"Drugs Aging"},{"key":"2553_CR11","doi-asserted-by":"publisher","first-page":"6509809","DOI":"10.1155\/2016\/6509809","volume":"2016","author":"P Harasymowycz","year":"2016","unstructured":"Harasymowycz P, Birt C, Gooi P, Heckler L, Hutnik C, Jinapriya D, et al. Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. Journal of ophthalmology. 2016;2016:6509809.","journal-title":"Journal of ophthalmology"},{"key":"2553_CR12","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet (London, England). 2015;385:1295\u2013304.","journal-title":"Lancet (London, England)"},{"key":"2553_CR13","doi-asserted-by":"crossref","unstructured":"Tumbocon JA, Macasaet AM. Efficacy and safety of tafluprost 0.0015% - retrospective analysis of real-world data from the Philippines. Clinical ophthalmology (Auckland, NZ). 2019;13:1627\u201334.","DOI":"10.2147\/OPTH.S209942"},{"key":"2553_CR14","unstructured":"Society EG. Terminology and guidelines for glaucoma (4th Edition). 2014. Available from: https:\/\/www.eugs.org\/eng\/guidelines.asp."},{"key":"2553_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.exer.2003.12.007","volume":"78","author":"Y Takagi","year":"2004","unstructured":"Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767\u201376.","journal-title":"Exp Eye Res"},{"key":"2553_CR16","doi-asserted-by":"crossref","unstructured":"Park SH, Yoo SH, Ha SJ. Comparison of Ocular Pulse Amplitude-Lowering Effects of Tafluprost and Latanoprost by Dynamic Contour Tonometry. Journal of ocular pharmacology and therapeutics\u202f: the official journal of the Association for Ocular Pharmacology and Therapeutics. 2015;31:617\u201322.","DOI":"10.1089\/jop.2014.0122"},{"key":"2553_CR17","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/OPTH.S108213","volume":"10","author":"Y Ikeda","year":"2016","unstructured":"Ikeda Y, Mori K, Tada K, Ueno M, Kinoshita S, Sotozono C. Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma. Clinical ophthalmology (Auckland, NZ). 2016;10:1633\u20137.","journal-title":"Clinical ophthalmology (Auckland, NZ)"},{"key":"2553_CR18","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1136\/bjophthalmol-2012-303026","volume":"97","author":"AG Konstas","year":"2013","unstructured":"Konstas AG, Quaranta L, Katsanos A, Riva I, Tsai JC, Giannopoulos T, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013;97:1510\u20135.","journal-title":"Br J Ophthalmol"},{"key":"2553_CR19","doi-asserted-by":"crossref","unstructured":"Shin J, Lee JW, Choi BS, Yun EY, Jung JH, Kim EA, et al. The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma. Journal of ocular pharmacology and therapeutics\u202f: the official journal of the Association for Ocular Pharmacology and Therapeutics. 2014;30:803\u20139.","DOI":"10.1089\/jop.2014.0034"},{"key":"2553_CR20","first-page":"623","volume":"5","author":"A Hommer","year":"2011","unstructured":"Hommer A, Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clinical ophthalmology (Auckland, NZ). 2011;5:623\u201331.","journal-title":"Clinical ophthalmology (Auckland, NZ)"},{"key":"2553_CR21","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s12325-017-0549-0","volume":"34","author":"Y Kuwayama","year":"2017","unstructured":"Kuwayama Y, Hashimoto M, Kakegawa R, Nomura A, Shimada F. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence. Adv Ther. 2017;34:1411\u201325.","journal-title":"Adv Ther"},{"key":"2553_CR22","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2147\/OPTH.S46340","volume":"7","author":"K Inoue","year":"2013","unstructured":"Inoue K, Tanaka A, Tomita G. Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma. Clinical ophthalmology (Auckland, NZ). 2013;7:1411\u20136.","journal-title":"Clinical ophthalmology (Auckland, NZ)"},{"key":"2553_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s12325-014-0109-9","volume":"31","author":"Y Kuwayama","year":"2014","unstructured":"Kuwayama Y, Nomura A. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther. 2014;31:461\u201371.","journal-title":"Adv Ther"},{"key":"2553_CR24","doi-asserted-by":"crossref","unstructured":"Erb C, Lanzl I, Seidova SF, Kimmich F. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Advances in therapy. 2011;28:575\u201385.","DOI":"10.1007\/s12325-011-0038-9"},{"key":"2553_CR25","first-page":"95","volume":"51","author":"J Ge","year":"2015","unstructured":"Ge J, Li X, Sun X, He X. Zhang H [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)]. Zhonghua Yan Ke Za Zhi. 2015;51:95\u2013102.","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"2553_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3109\/09286586.2012.708084","volume":"19","author":"Q Zhou","year":"2012","unstructured":"Zhou Q, Liang YB, Wong TY, Yang XH, Lian L, Zhu D, et al. Intraocular pressure and its relationship to ocular and systemic factors in a healthy Chinese rural population: the Handan Eye Study. Ophthalmic Epidemiol. 2012;19:278\u201384.","journal-title":"Ophthalmic Epidemiol"},{"key":"2553_CR27","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ophtha.2005.05.007","volume":"112","author":"JH Liu","year":"2005","unstructured":"Liu JH, Sit AJ, Weinreb RN. Variation of 24-hour intraocular pressure in healthy individuals: right eye versus left eye. Ophthalmology. 2005;112:1670\u20135.","journal-title":"Ophthalmology"},{"key":"2553_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/IEB.0b013e3182035809","volume":"12","author":"J Stein","year":"2011","unstructured":"Stein J. Diurnal intraocular pressure patterns are not repeatable in the short term in healthy individuals. Evid Based Ophthalmol. 2011;12:44\u20135.","journal-title":"Evid Based Ophthalmol"},{"key":"2553_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ajo.2018.10.017","volume":"199","author":"J Zhao","year":"2019","unstructured":"Zhao J, Solano MM, Oldenburg CE, Liu T, Wang Y, Wang N, et al. Prevalence of Normal-Tension Glaucoma in the Chinese Population: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2019;199:101\u201310.","journal-title":"Am J Ophthalmol"},{"key":"2553_CR30","first-page":"901","volume":"7","author":"I Lanzl","year":"2013","unstructured":"Lanzl I, Hamacher T, Rosbach K, Ramez MO, Rothe R, Ruzickova E, et al. Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension. Clinical ophthalmology (Auckland, NZ). 2013;7:901\u201310.","journal-title":"Clinical ophthalmology (Auckland, NZ)"},{"key":"2553_CR31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/ijcp.12815","volume":"70","author":"A Chabi","year":"2016","unstructured":"Chabi A, Baranak C, Lupinacci R, Herring WJ. Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial. Int J Clin Pract. 2016;70:577\u201386.","journal-title":"Int J Clin Pract"},{"key":"2553_CR32","doi-asserted-by":"crossref","unstructured":"Yang XT, Zhao L, Wang LJ, Zhang Y, Liao DY, Wang JM. Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis. Int J Ophthalmol. 2020;13:474\u201380.","DOI":"10.18240\/ijo.2020.03.16"},{"key":"2553_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/IIO.0b013e318187e8b5","volume":"48","author":"CC Geringer","year":"2008","unstructured":"Geringer CC, Imami NR. Medical management of glaucoma. Int Ophthalmol Clin. 2008;48:115\u201341.","journal-title":"Int Ophthalmol Clin"},{"issue":"Suppl 1","key":"2553_CR34","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.survophthal.2008.08.006","volume":"53","author":"AL Coleman","year":"2008","unstructured":"Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53(Suppl 1):S3-10.","journal-title":"Surv Ophthalmol"},{"key":"2553_CR35","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268\u201379.","journal-title":"Arch Ophthalmol"},{"key":"2553_CR36","doi-asserted-by":"crossref","unstructured":"Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE, et al. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126:1030\u20136.","DOI":"10.1001\/archopht.126.8.1030"},{"key":"2553_CR37","doi-asserted-by":"crossref","unstructured":"Hommer A, Mohammed Ramez O, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin. 2010;26:1905\u201313.","DOI":"10.1185\/03007995.2010.492030"},{"key":"2553_CR38","first-page":"1512","volume":"104","author":"A Hedengran","year":"2020","unstructured":"Hedengran A, Steensberg AT, Virgili G, Azuara-Blanco A, Kolko M. Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104:1512\u20138.","journal-title":"Br J Ophthalmol"},{"key":"2553_CR39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/IJG.0b013e318237c8b3","volume":"22","author":"S Tsuda","year":"2013","unstructured":"Tsuda S, Yokoyama Y, Chiba N, Aizawa N, Shiga Y, Yasuda M, et al. Effect of topical tafluprost on optic nerve head blood flow in patients with myopic disc type. J Glaucoma. 2013;22:398\u2013403.","journal-title":"J Glaucoma"},{"key":"2553_CR40","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1038\/s41598-017-05258-4","volume":"7","author":"Y Iida","year":"2017","unstructured":"Iida Y, Akagi T, Nakanishi H, Ohashi Ikeda H, Morooka S, Suda K, et al. Retinal Blood Flow Velocity Change in Parafoveal Capillary after Topical Tafluprost Treatment in Eyes with Primary Open-angle Glaucoma. Sci Rep. 2017;7:5019.","journal-title":"Sci Rep"},{"key":"2553_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.exer.2008.06.005","volume":"87","author":"Y Dong","year":"2008","unstructured":"Dong Y, Watabe H, Su G, Ishikawa H, Sato N, Yoshitomi T. Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteries. Exp Eye Res. 2008;87:251\u20136.","journal-title":"Exp Eye Res"},{"key":"2553_CR42","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.exer.2010.09.004","volume":"91","author":"H Kurashima","year":"2010","unstructured":"Kurashima H, Watabe H, Sato N, Abe S, Ishida N, Yoshitomi T. Effects of prostaglandin F(2\u03b1) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost. Exp Eye Res. 2010;91:853\u20139.","journal-title":"Exp Eye Res"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02553-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02553-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02553-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T14:03:56Z","timestamp":1659708236000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02553-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2553"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02553-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted at 11 centers in China and was approved by the Ethics Committee of Eye and ENT Hospital, Shanghai Medical College, Fudan University (Approval No. 2017008\u20131).; the Ethics Committee of Beijing Tongren Hospital, Capital Medical University (Approval No. TREC2017-62); the Ethics Committee of The Second Affiliated Hospital, Harbin Medical University (Approval No. 2017-MD-023); the Ethics Committee of Tianjin Eye Hospital (Approval No. TJYYLL-2017\u201311); the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Approval No. XHEC-C-2017\u2013037-2); the Ethics Committee of First Affiliated Hospital of Kunming Medical University (Approval No. 2017-YL-29); the Ethics Committee of The First Affiliated Hospital of Nanjing Medical University (Approval No. 2017-MD-214); the Ethics Committee of Qilu Hospital, Shandong University (Approval No. 2017040); the Ethics Committee of Tongji Medical College, Union Hospital, Huazhong University of Science & Technology (Approval No. 2017\u2013232); the Ethics Committee of The Second Affiliated Hospital, Zhejiang University School of Medicine (Approval No. 2017\u2013430); the Ethics Committee of Wuhan Eyegood Ophthalmic Hospital (Approval No. AG-BNZ-201805). All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"332"}}